Left Menu
Development News Edition

Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients

Noting that this positions India amongst the leading global innovators in their effort to overcome the COVID-19 pandemic, she said, the randomized control trial indicated that all the patients treated with Itolizumab (ALZUMAb) responded positively and recovered. Itolizumab is now approved for the treatment of CRS in patients with moderate to severe ARDS due to COVID-19.

PTI | Bengaluru | Updated: 11-07-2020 16:57 IST | Created: 11-07-2020 16:57 IST
Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients

Biotechnology major Biocon on Saturday announced that its "breakthrough drug," Itolizumab has received Drugs Controller General of India's (DCGI) approval for its use in moderate to severe COVID-19 patients. DCGI has approved to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19, Biocon said in a release.

It said Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19, it added.

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park here. "I am proud of the successful outcome of the pivotal study we conducted with our novel immuno-modulating anti-CD6 monoclonal antibody, Itolizumab, which has proven to be an efficacious intervention in treating the serious hyper immune response seen with COVID-19.

The data is compelling and I am confident that this first-in-class biologic will save lives and help reduce the mortality rate in our country," Biocon Executive Chairperson Kiran Mazumdar-Shaw said. Noting that this positions India amongst the leading global innovators in their effort to overcome the COVID-19 pandemic, she said, the randomized control trial indicated that all the patients treated with Itolizumab (ALZUMAb) responded positively and recovered.

Itolizumab is now approved for the treatment of CRS in patients with moderate to severe ARDS due to COVID-19. We plan to take this therapy to other parts of the world impacted by the pandemic, she added.

Biocon said the approval of Itolizumab from the DCGI is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi. The study focussed on the safety and efficacy of Itolizumab in preventing CRS in moderate to severe ARDS patients due to COVID-19, he said adding that the primary endpoints for reduction in mortality rate were met and other key secondary endpoints for efficacy and biomarkers were also achieved.


TRENDING

OPINION / BLOG / INTERVIEW

Canada’s COVID-19 pitfalls highlight need for integrated health information system

In the globalized world of today where outbreaks can spread far and wide within a matter of days, a global-level integrated health information system is ideal but Canadas provincial barriers show that the country lags much behind in deployi...

Pandemic must be impetus, not obstacle, for clean water access

To make matters worse, there are suspicions that the inadequacy of wastewater treatment methods in California, the rest of the USA, and indeed around the world may help to propagate the disease even more widely. ...

3D printing and the future of manufacturing post COVID-19

The on-demand, customizable, and localized manufacturing of product components facilitated by 3D printing has the potential to redefine manufacturing but there are certain technical, mechanical, and legal limitations that, unless ...

How UK’s 'best prepared' healthcare system failed to gauge COVID-19

The UK is proud of their public health system and its unlike any other country as around 90 percent of British public supports the founding principles of National Health Service. But without accurate data being available to stakeholders in ...

Videos

Latest News

Sebi bans 27 entities from mkts in matter of front running by Reliance Securities dealers, connected entities

Regulator Sebi has barred a number of individuals and entities from the capital market after it unearthed a major case of front running by some dealers of Reliance Securities Ltd and their connected entities by using their prior access to s...

James Anderson praises team environment as Ben Stokes leaves series for family issue

England pacer James Anderson has lauded the team environment after all-rounder Ben Stokes left the ongoing series with Pakistan midway to spend time with his family in New Zealand. On Sunday, England and Wales Cricket Board ECB announced th...

New Delhi, Aug 10 (PTI) These are the top stories of the northern region at 9 pm.

These are the top stories of the northern region at 9 pm. . DEL70 2NDLD RAHUL-SACHIN PILOT Rebel Cong leader Sachin Pilot meets Rahul Gandhi, Priyanka Gandhi Vadra amid hints of breakthrough New Delhi Ahead of the crucial Rajasthan as...

GRP arrests wanted criminal in Muzaffarnagar

The Government Railway Police GRP on Monday arrested a man, wanted in several cases, from the railway station here, an official said. Suraj was planning to commit robbery at the station. A pistol and some cartridges have been seized, the o...

Give Feedback